LIPUM BTA Stock Overview
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Lipum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr5.56 |
| 52 Week High | kr0 |
| 52 Week Low | kr0 |
| Beta | 0.11 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -7.49% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| LIPUM BTA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | 2.2% |
| 1Y | n/a | 2.0% | 16.1% |
Return vs Industry: Insufficient data to determine how LIPUM BTA performed against the Swedish Biotechs industry.
Return vs Market: Insufficient data to determine how LIPUM BTA performed against the Swedish Market.
Price Volatility
| LIPUM BTA volatility | |
|---|---|
| LIPUM BTA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: LIPUM BTA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LIPUM BTA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5 | Ola Sandborgh | www.lipum.se |
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular.
Lipum AB (publ) Fundamentals Summary
| LIPUM BTA fundamental statistics | |
|---|---|
| Market cap | kr140.00m |
| Earnings (TTM) | -kr37.18m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.8x
P/E RatioIs LIPUM BTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIPUM BTA income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr37.18m |
| Earnings | -kr37.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.75 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 38.5% |
How did LIPUM BTA perform over the long term?
See historical performance and comparison